Experimental HIV antibody suppresses deadly virus in monkeys

By :

New Ebola Vaccine for Exposure Risk

Researchers say an experimental HIV antibody tested on a group of monkeys successfully suppressed the deadly virus for nearly six months without additional treatment. The new findings may inform strategies that attempt to achieve sustained, drug-free viral remission in people living with HIV. After receiving a course of antiretroviral therapy for their HIV-like infection, approximately half of a group of monkeys infused with a broadly neutralising antibody to HIV combined with an immune stimulatory compound suppressed the virus for six months without additional treatment, said the study. The study noted the therapy may have targeted the viral reservoir -- populations of long-lived, latently infected cells that harbor the virus and that lead to resurgent viral replication when suppressive therapy is stopped. “HIV excels at evading the immune system by hiding out in certain immune cells,” said Anthony S Fauci, Director at the National Institute of Allergy and Infectious Diseases (NIAID) in Maryland, US. “The virus can be suppressed to very low levels with antiretroviral therapy, but quickly rebounds to high levels if a person stops taking medications as prescribed. The findings from this early stage research offer further evidence that achieving sustained viral remission without daily medication might be possible,” he added, in a paper released at the 25th Conference on Retroviruses and Opportunistic Infections in Boston. In the study, scientists infected 44 rhesus macaques with simian-human immunodeficiency virus (SHIV), an HIV-like virus commonly used in nonhuman primate studies. They then initiated daily antiretroviral therapy (ART) for 96-weeks, during acute infection to suppress the virus to below detectable levels in the monkey's blood. After discontinuation of ART, the virus rebounded in the blood of all monkeys that neither received HIV antibodies or immune stimulant after a median of 21 days. The group of monkeys who received the therapy combination showed a delayed viral rebound after a median of 112 days, another group did not rebound for at least 168 days. “Our findings suggest that the development of interventions to activate and eliminate a fraction of the viral reservoir might be possible,” the researchers said. Compared with the antiretroviral therapy which needs to be taken daily, antibodies to HIV tend to last longer in the body and have shown promise for longer-acting HIV therapeutics and prevention modalities, they noted. Examining how this occurred, and expanding on this strategy, may help scientists determine a way to safely reduce the viral reservoir in humans, with the eventual goal of allowing people living with HIV to suppress the virus without regular medication. -------------------------- (News Source :Times Now Digital, Agencies) #HIV #Virus #antibody
Rate UsDon’t love itNot greatGoodGreatLove itRate Us
Your opinion
arrow&v
arrow&v

PHAF Team

FDA Approves Audenz as First-Ever Adjuvanted, Cell-Based Pandemic Influenza A (H5N1) Vaccine

PHAF Team

Antibiotics In common cold – Yes or NO.

Dr. Ateendra Jha

Father's X chromosome has clues to autoimmune disease in females.

PHAF DIC Team

Self Medication

Dr. Ateendra Jha

Man Died of Sepsis and Organ Failure Within Weeks of Being Licked by His Pet

PHAF Team

WHO Launches New Polio Vaccine In 150 Countries

© 2019 PHAF  || All rights reserved

  • Facebook Social Icon
  • Twitter Social Icon
  • Google+ Social Icon
  • YouTube Social  Icon
  • Instagram Social Icon

Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a healthcare professional.